1. Clinical & Scientific Overview
Sucralfate (TIP-MED-000079, Reference Code [5.11]) is classified under
Gastrointestinal & Hepatobiliary Medicines (Ch 05) as a Cytoprotective Mucosal Barrier Agent (Sucrose Octasulfate–Aluminium Hydroxide Complex).
Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).
Representative Indian Market Examples (Edition 2.7 Ch 05 [5.11], p. 65): Sucrafil (Fourts India), Sparacid, Pepsigard; In Suspension with Oxetacaine (Topical Anaesthetic): Sucrafil-O Gel (Fourts) — Strengths & Dosage Forms: Oral Suspension: 1 g / 10 mL (or 1 g / 5 mL); Oral Uncoated Tablets: 1 g
Oral Suspension: 1 g / 10 mL (or 1 g / 5 mL); Oral Uncoated Tablets: 1 g
3. Mechanism of Action & Pharmacodynamics
Cytoprotective Mucosal Barrier Agent (Sucrose Octasulfate–Aluminium Hydroxide Complex) acting on target receptor/enzyme pathways in Gastrointestinal & Hepatobiliary Medicines (Ch 05): clinical efficacy is mediated via Cytoprotective Mucosal Barrier Agent (Sucrose Octasulfate–Aluminium Hydroxide Complex) for Duodenal and gastric ulcer healing; bile reflux gastritis; radiation/chemotherapy mucositis and stress ulcer prophylaxis; symptomatic relief of painful erosive oesophagitis (especially with oxetacaine)..
4. Therapeutic Indications & Evidence-Supported Uses
- Duodenal and gastric ulcer healing
- bile reflux gastritis
- radiation/chemotherapy mucositis and stress ulcer prophylaxis
- symptomatic relief of painful erosive oesophagitis (especially with oxetacaine)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: 1 g (10 mL suspension or 1 tablet) four times daily (1 hour before each of the 3 main meals and at bedtime), or 2 g twice daily for 4–8 weeks. Follow physician prescription.
Administration & Meal Timing: Strictly on an EMPTY STOMACH: 1 hour BEFORE meals and at bedtime! (In an acidic environment [pH <4], sucralfate polymerises into a viscous, sticky yellow-white paste that electrostatically binds positively charged proteins in raw ulcer craters for up to 6 hours, shielding the ulcer before food and acid arrive). | Four times daily: 1 hour before breakfast, 1 hour before lunch, 1 hour before dinner, and at bedtime.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Strictly renal-function dependent! Small amounts of aluminium are absorbed from the gut and excreted by the kidneys; in CKD Stage 4–5 (eGFR <30 mL/min), aluminium accumulates in brain and bone—avoid in severe CKD. Hepatic: Safe (commonly used post-variceal banding to heal oesophageal ulcers).
Renal: Strictly renal-function dependent! Small amounts of aluminium are absorbed from the gut and excreted by the kidneys; in CKD Stage 4–5 (eGFR <30 mL/min), aluminium accumulates in brain and bone—avoid in severe CKD. Hepatic: Safe (commonly used post-variceal banding to heal oesophageal ulcers).
Renal: Strictly renal-function dependent! Small amounts of aluminium are absorbed from the gut and excreted by the kidneys; in CKD Stage 4–5 (eGFR <30 mL/min), aluminium accumulates in brain and bone—avoid in severe CKD. Hepatic: Safe (commonly used post-variceal banding to heal oesophageal ulcers).
7. Contraindications, Precautions & High-Risk Warnings
- Avoid or use with extreme caution in chronic kidney disease (eGFR <30 mL/min or dialysis) due to systemic absorption of aluminium! Do not administer intravenously. Caution in patients with impaired swallowing/dysphagia or delayed gastric emptying (risk of gastric bezoar formation with enteral tube feeds).
Key Clinical Precautions: Renal: Strictly renal-function dependent! Small amounts of aluminium are absorbed from the gut and excreted by the kidneys; in CKD Stage 4–5 (eGFR <30 mL/min), aluminium accumulates in brain and bone—avoid in severe CKD. Hepatic: Safe (commonly used post-variceal banding to heal oesophageal ulcers).
8. Adverse Effects Profile
- Constipation (2–10%, due to aluminium content), dry mouth, nausea.
- Aluminium toxicity / encephalopathy and osteomalacia in patients with renal failure (CKD Stages 4–5), intestinal or oesophageal bezoar obstruction (in critically ill tube-fed patients).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Massive Chelation & Adsorption Interaction Profile: Because sucralfate contains aluminium and forms a physical barrier, it binds and blocks the absorption of Fluoroquinolones (ciprofloxacin, levofloxacin, ofloxacin), Tetracyclines (doxycycline), Levothyroxine, Digoxin, Warfarin, Phenytoin, Ketoconazole, and Bisphosphonates—administer these medications at least 2 hours BEFORE (or 4–6 hours after) sucralfate! Furthermore, do not take antacids within 30 minutes before or after sucralfate, as raising gastric pH prevents sucralfate from polymerising into its active protective gel
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Shake the suspension bottle well before every dose. Explain that sucralfate acts like a 'liquid bandage' over stomach ulcers and must be taken 1 hour before meals on an empty stomach. Enforce a strict 2-hour gap from thyroid tablets, antibiotics, blood thinners, and antacids.
- Meal & Clock Timing Instruction: Strictly on an EMPTY STOMACH: 1 hour BEFORE meals and at bedtime! (In an acidic environment [pH <4], sucralfate polymerises into a viscous, sticky yellow-white paste that electrostatically binds positively charged proteins in raw ulcer craters for up to 6 hours, shielding the ulcer before food and acid arrive). (Four times daily: 1 hour before breakfast, 1 hour before lunch, 1 hour before dinner, and at bedtime.)
- Missed Dose Protocol: Take as soon as remembered on an empty stomach; skip if right at mealtime or close to the next dose.
- Geriatric Dispensing Pearl: Because elderly patients frequently have reduced eGFR, chronic constipation, and take multiple interacting medications (levothyroxine, digoxin, warfarin, ciprofloxacin), sucralfate requires careful scheduling and must be avoided in advanced CKD.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Suspension: 1 g / 10 mL (or 1 g / 5 mL); Oral Uncoated Tablets: 1 g
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 05 [5.11] (p. 65)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [5.15] Itopride Hydrochloride & Acotiamide — Peripheral D2 Antagonist + Acetylcholinesterase Inhibitor Gastrop
- [5.16] Metoclopramide Hydrochloride — Central & Peripheral Dopamine D2 Antagonist & 5-HT4 Agonist Antie
- [5.17] Ispaghula Husk (Psyllium) & Liquid Paraffin Emulsions — Bulk-Forming Soluble Fibre Laxative & Faecal Lubricant/Osmotic Co
- [5.18] Loperamide Hydrochloride & Racecadotril — Peripheral Mu-Opioid Antidiarrhoeal & Antisecretory Enkephalinase
